Compare CD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CD | NMRA |
|---|---|---|
| Founded | 2011 | 2019 |
| Country | United States | United States |
| Employees | 11 | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.6M | 424.4M |
| IPO Year | N/A | 2023 |
| Metric | CD | NMRA |
|---|---|---|
| Price | $6.11 | $2.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 156.5K | ★ 2.4M |
| Earning Date | 08-31-2023 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $956,830.00 | N/A |
| Revenue This Year | $949,544.10 | N/A |
| Revenue Next Year | $14.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 33.48 | N/A |
| 52 Week Low | $1.38 | $0.61 |
| 52 Week High | $36.77 | $3.25 |
| Indicator | CD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.18 |
| Support Level | N/A | $1.84 |
| Resistance Level | N/A | $2.18 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 52.34 |
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.